BLTE vs. BPMC, ELAN, ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, and ABVX
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.
Belite Bio vs. Its Competitors
Blueprint Medicines (NASDAQ:BPMC) and Belite Bio (NASDAQ:BLTE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.
In the previous week, Belite Bio had 14 more articles in the media than Blueprint Medicines. MarketBeat recorded 15 mentions for Belite Bio and 1 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.00 beat Belite Bio's score of -0.24 indicating that Blueprint Medicines is being referred to more favorably in the media.
Belite Bio has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.
Belite Bio has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. Belite Bio's return on equity of -34.90% beat Blueprint Medicines' return on equity.
Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.49, meaning that its stock price is 249% less volatile than the S&P 500.
0.5% of Belite Bio shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Blueprint Medicines currently has a consensus price target of $130.00, indicating a potential upside of 0.42%. Belite Bio has a consensus price target of $96.67, indicating a potential upside of 56.39%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Belite Bio is more favorable than Blueprint Medicines.
Summary
Belite Bio beats Blueprint Medicines on 11 of the 15 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
This page (NASDAQ:BLTE) was last updated on 8/20/2025 by MarketBeat.com Staff
MarketBeat All Access